De‐risking Clinical Trials: The BIAL Phase I Trial in Foresight-Reference-Cited by-同舟云学术

De‐risking Clinical Trials: The BIAL Phase I Trial in Foresight

Published:2021-12-28 Issue:2 Volume:111 Page:362-365
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Cohen Adam F.¹²,van Smeden Jeroen²³⁴^ORCID,Webb David J.⁵

Affiliation:

1. DDCD Consulting Leiden The Netherlands

2. Leiden University Medical Center Leiden The Netherlands

3. Leiden Academic Centre for Drug Research University of Leiden Leiden The Netherlands

4. Centre for Human Drug Research Leiden The Netherlands

5. Pharmacology, Toxicology and Therapeutics Centre for Cardiovascular Science The University of Edinburgh Scotland UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2498

Reference12 articles.

1. Safety, tolerability, and pharmacokinetics of FAAH inhibitor BIA 10–2474: a double‐blind, randomized, placebo‐controlled study in healthy volunteers;Rocha J.F.;Clin. Pharmacol. Ther.

2. On authorship in the BJCP

3. British Pharmacological Society.Improve early access to data from catastrophic clinical trials: a statement on behalf of the British Pharmacological Society [press release] (2016).

4. BIAL ‐ Portela & C SA.Clinical Study Protocol No. BIA‐102474‐101 (2015).

5. Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The estimation and translation uncertainties in applying NOAEL to clinical dose escalation;Clinical and Translational Science;2024-05-29

2. Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2;British Journal of Clinical Pharmacology;2023-11-22

3. Anxiolytic effects of endocannabinoid enhancing compounds: A systematic review and meta-analysis;European Neuropsychopharmacology;2023-07

4. Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs;Translational Psychiatry;2023-03-01

5. Research and discovery: Essential partners but just a start;Managing the Drug Discovery Process;2023